Honeycomb-like arrays of tiny, lab-grown cancers could one day help doctors zero in on individualized treatments for ovarian cancer, an unpredictable disease that kills more than 14,000 women each year in the United States alone.
Research has shown that whether or not a patient is married makes a difference in how well -- or not -- a patient does, including for patients with cancer. What researchers don't understand is exactly why being married makes such a difference.
According to new research by Michigan Medicine, more than 10 percent of people who had never taken opioids prior to curative-intent surgery for cancer continued to take the drugs three to six months later. The risk is even greater for those who are treated with chemotherapy after surgery.
Women who pursue a more aggressive surgery for early stage breast cancer have nearly eight times the odds of reporting substantial employment disruptions, according to a new study from University of Michigan Comprehensive Cancer Center researchers.
The Stanford Medicine Alumni Association has announced that Max S. Wicha, M.D., will receive the prestigious J. E. Wallace Sterling Lifetime Achievement Award in Medicine. He will be honored at a dinner held on the Stanford School of Medicine campus on December 9.
To understand cervical cancer in Ethiopia, U-M’s Rozek has developed a new screening and survey of women. She hopes to compare it with results from other countries in Asia and the Middle East.
Tobacco Control Policy (TCP) tool is a simulation model and web-based tool, hosted at the U-M School of Public Health, which can help predict the potential state-by-state impact of changing policies, such as raising cigarette taxes, implementing smoke-free air laws and increasing tobacco control expenditures on deaths avoided and years of life gained.
In the hunt for novel treatments against an aggressive form of breast cancer, University of Michigan researchers recently combined a new protein inhibitor with a chemotherapy drug.
A new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. It is already in use in a breast cancer clinical trial.
Immune response prognostic for prostate cancer survival, recurrence and response to radiation therapy
A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to radiation therapy, as well as their likelihood of disease recurrence and survival outcomes.